Search Results

Pharnext SA announces the conclusion of an agreement with Neovacs for the establishment by Neovacs of a management trust, with Equitis Gestion as trustee, to exercise all of the rights and satisfy all of the obligations of the latter as well as manage the Pharnext securities issued by Pharnext respectively to Neovacs and the Trust, respectively, under the OBSA Agreement signed on September 30th, 2022 between Pharnext and Neovacs.

Pharnext SA announces a series of decisions that have been made to secure the next steps in its development with the support of Néovacs, a French biotech company focused on therapeutic vaccines targeting the treatment of autoimmune diseases and support for promising BioTech and MedTech companies, following the financing and strategic support agreement announced by Pharnext on October 3rd, 2022[1].

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Scott Johnson as VP, Head of Quality.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces its financial results for the first half of 2022.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Dr. Rob Quinn as Chief Financial Officer, effective immediately.

Pharnext SA announces that at its Annual General Meeting on Friday June 17th all key resolutions proposed by the Pharnext Board of Directors were adopted.

Pharnext SA announces that its Board of Directors decided to perform a reverse stock split on the shares comprising its capital stock whereby one new share with a nominal value of 1 euro will equal 5,000 old shares with a nominal value of 0.0002 euro, as authorized by Shareholders’ meeting held on June 17th, 2022 under resolution # 8.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Antoine Gravelle as General Counsel, effective July 1st, 2022.

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the signing of a €2.5 million loan agreement with Néovacs, a French biotechnology company listed on Euronext Growth Paris.

Pharnext SA announces the signature of a financing agreement, by which Néovacs, a French biotech company focused on therapeutic vaccines targeting the treatment of autoimmune diseases and investment support of promising biotech and medtech companies, undertakes to subscribe to simple obligations to be issued by Pharnext in an issuance program spanning until July 2023, for a total nominal amount of EUR 21,093,800 .